Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLXTE-HAase02 in Healthy Chinese Adult Male Subjects
NCT07484893Phase 1Not yet recruiting
- Sponsor
- Henlius
- Start
- May 2026
- Primary completion
- Aug 2026
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HLXTE-HAase02, sponsored by Henlius. Primary endpoints: Incidence of Adverse Events and Serious Adverse Events, Incidence of hypersensitivity reactions and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
HLXTE-HAase02
Beyond the preview
Go deeper on NCT07484893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07484893.